Ketogenic Diet for Prevention of Epileptic Spasms in Infantile Onset Genetic Epilepsies
Phase 1 Study of Ketogenic Diet for Prevention of Epileptic Spasms in Infantile Onset Genetic Epilepsies
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Heather E Olson, MD, MS
- Phone Number: 617-355-7970
- Email: Heather.Olson@childrens.harvard.edu
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Recruiting
- Boston Children's Hospital
-
Contact:
- Jessica Landers, MS
- Phone Number: 617-355-0578
- Email: jessica.landers@childrens.harvard.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Plan for initiation of ketogenic diet by clinical team for treatment of epilepsy
- The clinical team initiating the ketogenic diet agrees that the use of the KetoVie formula is appropriate for the subject, as all study subjects need to receive the same formula
- Male or female, age 0 to less than 9 months (including neonates per investigator's judgment)
- Epilepsy onset at less than 6 months of age
- Abnormal development (any sub score of the Bayley-4 less than 1 standard deviation below the mean) and/or neurologic exam (microcephaly, macrocephaly, strabismus, abnormal vision/CVI, hypotonia, spasticity, dystonia, movement disorder), per investigators judgment
- Suspected or confirmed genetic diagnosis as a cause for epilepsy
- Weight adequate to complete required study laboratory testing without exceeding maximum allowable blood draws per draw or in a 30 day period per BCH policy
Exclusion Criteria:
- Epileptic spams prior to enrollment
- Tuberous sclerosis complex, trisomy 21 (based on differential response to ES treatment)
- Metabolic diagnosis with targeted treatment (including specific indication for ketogenic diet such as glucose transporter disorder, vitamin dependent epilepsies, and others) or exclusion for the ketogenic diet
- Ongoing treatment with vigabatrin, ACTH, corticosteroids, topiramate or zonisamide. Other anti-seizure medications are permitted.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Ketogenic diet
KetoVie® 4:1 Formula will be administered by oral feeding or gastrostomy tube as indicated.
The duration of the diet will be from the time of enrollment up to 12 months of age or until 3 months after a diagnosis of Epileptic Spasms (range 3-15 months).
|
The ketogenic diet formula will be KetoVie®, supplied by Ajinomoto Cambrooke.
Ketogenic diet ratio will aim to achieve ketosis, with a minimum level of beta-hydroxybutyrate of 1.0mmol/L.
Ratios of ketogenic diet generally range from 1:1 to 4:1.
Ratio will increase per standard clinical care for ketogenic diet initiation.
For the trial we will aim to reach a maximum of 4:1 by the 6 week follow-up visit, but stopping at a lower ratio if BHB is ≥ 5mmol/L, CO2 ≤ 18 mmol/L, for tolerance, or to meet protein needs.
A minimum 1:1 ratio is required to continue in the trial.
Ratios higher than 1:1 are often required to obtain ketosis of ideally 2-5mmol/L in infants.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Achievement of ketosis
Time Frame: rom ketogenic diet initiation until 3 months after the diagnosis of ES (if it occurs) or until 12 months of age
|
Proportion of subjects assigned to ketogenic diet who achieve ketosis by 6 weeks and maintain a minimum ratio of 1:1 through 3 months after onset of epileptic spasms (ES) or 12 months of age
|
rom ketogenic diet initiation until 3 months after the diagnosis of ES (if it occurs) or until 12 months of age
|
|
EEG compliance
Time Frame: From ketogenic diet initiation until the onset of ES (if it occurs) or until 12 months of age
|
Proportion of subjects who complete EEGs every 6 weeks (+/- 2 weeks) until onset of ES or 12 months of age
|
From ketogenic diet initiation until the onset of ES (if it occurs) or until 12 months of age
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Epileptic Spasms Outcome
Time Frame: From ketogenic diet initiation until 12 months of age
|
Proportion of subjects who develop ES by 12 months of age
|
From ketogenic diet initiation until 12 months of age
|
|
EEG Outcome
Time Frame: From ketogenic diet initiation until 12 months of age
|
Proportion of enrolled subjects for whom a study EEG identified ES or identified hypsarrhythmia with subsequent workup leading to diagnosis of ES prior to clinical suspicion
|
From ketogenic diet initiation until 12 months of age
|
|
Safety Outcome
Time Frame: From ketogenic diet initiation until the diet is weaned (up to 18 months of age)
|
To assess safety of ketogenic diet treatment in infants with suspected or confirmed genetic DEEs by monitoring the rate of serious adverse events and adverse events, expected and unexpected
|
From ketogenic diet initiation until the diet is weaned (up to 18 months of age)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Epileptic Syndromes
- Neurologic Manifestations
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Epilepsy, Generalized
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Drug Resistant Epilepsy
- Epilepsy
- Seizures
- Spasms, Infantile
- Therapeutics
- Diet, Food, and Nutrition
- Physiological Phenomena
- Nutritional Physiological Phenomena
- Diet Therapy
- Nutrition Therapy
- Diet
- Diet, Carbohydrate-Restricted
- Diet, Ketogenic
Other Study ID Numbers
Other Study ID Numbers
- P00047586
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.